BOSTON — (BUSINESS WIRE) — Silicon Therapeutics (SiTX) announced today that Pamela Carroll, Ph.D. has been appointed Chief Business Officer to lead corporate strategy and business development. Dr. Carroll joins Silicon Therapeutics after more than 20 years in senior research and leadership positions at Johnson & Johnson, Roche, the Dana Farber Cancer Institute, and most recently at Genocea Biosciences, where she served as Senior Vice President of Immuno-oncology.
“Silicon Therapeutics is at the forefront of using computational physics to simulate biologically-relevant protein motion,” said Dr. Carroll. “This, coupled with an integrated research and development team, will deliver transformational medicines to patients. SiTX’s rapid success addressing challenging targets shows its enormous potential and creates an array of strategic business opportunities.”
“We are excited to have Pam spearheading our corporate development and strategy initiatives. Her extensive experience at the intersection of business, strategy and drug discovery is a unique fit for Silicon Therapeutics,” said Lanny Sun, CEO & Co-founder of Silicon Therapeutics.
At Genocea Biosciences, Dr. Carroll led the company’s development of vaccines and cell therapies. Prior to Genocea, Dr. Carroll held the position of Vice President at Janssen Oncology-Johnson and Johnson Innovation, where she led strategic partnerships, new company investments and academic collaborations. Additionally, she successfully led drug discovery efforts as Vice President of Roche Oncology Discovery and Head of Research at the Belfer Institute for Applied Cancer Sciences at the Dana Farber Cancer Center and Harvard Medical School. Earlier in her career Dr. Carroll served as Director of Cancer Pathways at Merck Research Laboratories and Senior Investigator in Applied Genomics at Bristol Myers Squibb. Dr. Carroll received a bachelor’s degree in biology from Saint Michael’s College in Vermont, a doctorate in cell biology from Stony Brook University and completed a postdoctoral fellowship at Stanford University.
About Silicon Therapeutics
Silicon Therapeutics (“SiTX”) is a physics-driven drug discovery company focused on small molecule therapeutics. The company’s proprietary platform can accurately simulate the physical motion and properties of biological targets and ligands at atomic resolution, revealing essential drug design insights to overcome critical bottlenecks in projects. The platform is cohesively integrated with a world-class wet lab including biophysics, chemistry, and biology, enabling rapid hypothesis-driven data generation to advance drug discovery projects on targets that have traditionally been considered undruggable. The SiTX lead program is a small molecule STING agonist for systemic delivery in immuno-oncology that is slated to enter the clinic in late 2020.
Learn more at www.silicontx.com.
RMG Associates, LLC